DCM Advisors’s Biolase BIOL Stock Holding History
Bought
Maintained
Sold
Other funds holding BIOL
DCM Advisors's BIOL Position: Q1 2022 in Review
DCM Advisors sold out of Biolase (BIOL) in Q1 2022, closing a stake of 7 shares — an estimated $6K sold.
DCM Advisors first reported a position in BIOL in Q1 2021 and held it in 4 quarters. The position peaked at $101K in Q1 2021. 27 funds tracked by Wall St. Rank hold BIOL as of Q1 2022.
- DCM Advisors reported no remaining Biolase position as of Q1 2022 after selling out during the quarter.
- DCM Advisors sold 7 Biolase shares in Q1 2022, an estimated $6K.
- DCM Advisors first reported a position in Biolase in Q1 2021 and held it in 4 quarters.
- DCM Advisors's Biolase position peaked at $101K in Q1 2021.
- 27 funds tracked by Wall St. Rank held Biolase as of Q1 2022.
Based on DCM Advisors's 13F filing for Q1 2022, filed 9 May 2022.